Microbion Corporation Revenue
Pharmaceutical Manufacturing • 
Bozeman, Montana, United States • 11-20 Employees
Microbion Corporation revenue & valuation
| Annual revenue | $13,500,000 |
| Revenue per employee | $900,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $43,200,000 |
| Total funding | $4,099,999 |
Key Contacts at Microbion Corporation
Edmond Lee
Director, Business Operations
Georgia Baker
Director Of Marketing And Communications
Company overview
| Headquarters | 5 West Mendenhall Street, Suite 202, Bozeman, Montana 59715, US |
| Phone number | +14062336472 |
| Website | |
| NAICS | 3254 |
| SIC | 873 |
| Keywords | Biotechnology, Medical Device Coatings, Pharmaceutical Drugs |
| Founded | 2000 |
| Employees | 11-20 |
| Socials |
Microbion Corporation Email Formats
Microbion Corporation uses 4 email formats. The most common is {first initial}{last name} (e.g., jdoe@microbioncorp.com), used 28.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@microbioncorp.com | 28.6% |
{first initial}{last name}{first initial}{first initial} | jdoejj@microbioncorp.com | 28.6% |
{last name}{last name} | doedoe@microbioncorp.com | 28.6% |
{first name}{last name} | johndoe@microbioncorp.com | 14.3% |
About Microbion Corporation
At Microbion, we are developing a new class of therapeutic drugs to tackle the unmet needs of rare, chronic, and serious diseases. Our lead drug candidate, pravibismane, is a first-in-class therapeutic with a novel triad of activities: anti-infective, antibiofilm, and anti-inflammatory. These synergistic properties uniquely position pravibismane to address conditions where conventional treatments often fail. We are advancing multiple pravibismane formulations through clinical development, focusing on indications with significant unmet needs: - Topical pravibismane for diabetic foot ulcers/infections: Phase 3 studies planned for 2025 - Local/surgical pravibismane for orthopedic infections: Phase 2a studies completed - Inhaled pravibismane for pulmonary diseases including Nontuberculous mycobacteria lung infections: Ready for first-in-human Phase 1 studies Pravibismane has been granted FDA Qualified Infectious Disease Product (QIDP), Fast Track, and Orphan Drug designations, underscoring its disruptive potential. To date, pravibismane development has been supported by over $22M in grants awarded from leading organizations, including the U.S. Department of Defense, NIH, CARB-X, and the Cystic Fibrosis Foundation. We are actively seeking strategic licensing and development partners to advance Phase 3 trials, explore new indications (e.g., immunomodulation and inflammation), and bring pravibismane to patients worldwide.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Microbion Corporation has 5 employees across 5 departments.
Departments
Number of employees
Microbion Corporation Tech Stack
Discover the technologies and tools that power Microbion Corporation's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Security
Miscellaneous
CDN
JavaScript libraries
Analytics
Font scripts
CDN
PaaS
Tag managers
Belgium
Poland
Frequently asked questions
4.8
40,000 users
